Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the 2013 UBS Global Healthcare Conference in New York.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 2 study (Study 101-08) evaluating idelalisib (formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K delta, in combination with rituximab for older patients with ...

Calls were the options of choice on Gilead Sciences, Inc. (NASDAQ:GILD) yesterday, with roughly 27,000 contracts crossing the tape during the course of the session.

Gilead Sciences, Inc. (NASDAQ:GILD) : By the end of last trading session, Gilead Sciences (NASDAQ:GILD) shares earned US$1.59 (or 3.01%) to US$54.47 with about 14.49 million shares exchanged hands for the session, compared to its average volume of ...

Gilead Sciences Inc. (NASDAQ:GILD) a biopharmaceutical company that discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia is currently up (+2.94%) on 10,887,989 ...

(RTTNews.com) - Gilead Sciences Inc. ( GILD ) will present at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas.

NEW YORK (AP) - Shares of Gilead Sciences Inc. rose to all-time highs Friday after the company reported its first-quarter results and new trial data for two of its experimental hepatitis C drugs.

Gilead Sciences, Inc (GILD) recently disclosed that it will webcast its corporate presentation from the 2013 UBS Global Healthcare Conference in New York.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2013 financial results will be released on Thursday, May 2, at 4:05 p.m.

The market celebrated the first quarter results of Gilead Sciences, Inc.(NASDAQ:GILD) by sending the shares of the company to an all-time high on Friday.